Furthermore, investigating targeted therapeutic options that span the tumor spectrum, such as antibody–drug conjugates (ADCs) targeting the TROP2 antigen, may offer innovative treatment modalities for the management of MPMs. The gene discussed is TACSTD2; the disease is neoplasm.